Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers

Chronobiology International

Volumn 20, Issue 3, 2003, Pages 485-494

  Flores Pérez, Janett ^a   Juàrez Olguín, Hugo ^a,b   Flores Pérez, Carmen ^a   Pérez Guillé, Gabriela ^a   Guillé Pérez, Adrián ^a   Camacho Vieyra, Angélica ^a   Toledo López, Alejandra ^a   Carrasco Portugal, Miriam ^a   Lares Asseff, Ismael ^a,c  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Chronopharmacology; Gender; Menstrual cycle; Pharmacokinetics; Ranitidine

Indexed keywords

RANITIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FOLLICULAR PHASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADULT; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MENSTRUAL CYCLE; MIDDLE AGED; RANITIDINE; SEX FACTORS;

EID: 0038007197     PISSN: 07420528     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Abad-Santos, F., Carcas, A. J., Guerra, P., Govantes, C., Montuenga, C., Gómez, E. (1996). Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J. Clin. Pharmacol. 36(8):748-751.
2. Beierle, I., Meibohm, B., Derendorf, H. (1999). Gender differences in pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 37(11):529-547.
3. Bonate, P. L. (1991). Gender-related differences in xenobiotic metabolism. J. Clin. Pharmacol. 31(8):684-690.
4. Brandstetter, Y., Kaplanski, J., Leibson, V., Ben-Zvi, Z. (1986). The effects of estrus cycle on drug metabolism in the rat. Eur. J. Drug Metab. Pharmacokinet. 11(4):251-254.
5. Brogden, R. N., Carmine, A. A., Heel, R. C., Speight, T. M., Avery, G. S. (1982). Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24(4):267-303.
6. Bruguerolle, B. (1983). The menstrual cycle and drug pharmacokinetics. J. Gynecol. Obstet. Biol. Reprod. (Paris) 12(8):825-827.
7. Bruguerolle, B. (1992). Caffeine kinetic changes during the oestrous cycle in rats. Fundam. Clin. Pharmacol. 6(1):45-48.
8. Bruguerolle, B., Grignon, S. (1996). Chronopharmacology. Pathol. Biol. 44(6):547-554.
9. Crippens, D., White, M. L., George, M. A., Jaworski, J. N., Brunner, L. J., Lancaster, F. E., Gonzales, R. A. (1999). Gender differences in blood levels, but not brain levels, of ethanol in rats. Alcohol Clin. Exp. Res. 23(3):414-420.
10. Fletcher, C. V., Acosta, E. P., Strykowski, J. M. (1994). Gender differences in human pharmacokinetics and pharmacodynamics. J. Adolesc. Health 15(8):619-629.
11. Gleiter, C. H., Gundert-Remy, U. (1996). Gender differences in pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 21(2):123-128.
12. Grant, S. M., Langtry, H. D., Brogden, R. N. (1989). Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37(6):801-870.
13. Harris, R. Z., Benet, L. Z., Schwartz, J. B. (1995). Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2):222-239.
14. Hooper, W. D., Qing, M. S. (1990). The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin. Phramacol. Ther. 48(6):633-640.
15. Kashuba, A. D., Nafziger, A. N. (1998). Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin. Pharmacokinet. 34(3):203-218.
16. Khosla, S., Somberg, J. C. (1996). Gender differences in drug therapy. Am. J. Ther. 3(10):735-739.
17. Lane, J. D., Steege, J. F., Rupp, S. L., Kuhn, C. M. (1992). Menstrual cycle effects on caffeine elimination in the human female. Eur. J. Pharmacol. 43(5):543-546.
18. Meibohm, B., Beierle, I., Derendorf, H. (2002). How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41(5):329-342.
19. Quinones-Jenab, V., Ho, A., Schlussman, S. D., Franck, J., Kreek, M. J. (1999). Estrous cycle differences in cocaine-induced stereotypic and locomotor behaviors in Fischer rats. Behav. Brain Res. 101(1):15-20.
20. Roberts, C. J. (1984). Clinical pharmacokinetics of ranitidine. Clin. Pharmacokinet. 9(3):211-221.
21. Rodríguez-Pérez, R., Barragán-Mejía, M.G., Castilla-Serna, L. (1992). Paquest version 1.0 Biomedical Software Developed S. de R.L. de C.V. México.
22. Rukstalis, M., De Wit, H. (1999). Effects of triazolam at three phases of the menstrual cycle. J. Clin. Psychopharmacol. 19(5):450-458.
23. Tanaka, E. (1999). Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther. 24(5):339-346.
24. Vinge, E. (1998). Men and women respond differently to drugs. Hormone-dependent pharmacodynamic differences are rarely studied. Lakartidningen 95(28-29):3177-3182.
25. Walle, T., Walle, K., Cowart, T. D., Conradi, E. C. (1989). Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin. Pharmacol. Ther. 46(3):257-263.
26. Williamson, B. S. (1983). Ranitidine. J. Am. Med. Assoc. 250(14):1894-1896.
27. Win-nonlin Program, Standard Edition, Version 1.1. (1991). Mountain View, CA: Scientific Consulting Inc.,
28. Wojcicki, J., Gawronska-Szklarz, B., Kazimierczyk, J., Baskiewicz, Z., Raczynski, A. (1979). Comparative pharmacokinetics of paracetamol in men and women considering follicular and luteal phases. Arzneimittelforschung 29(2):350-352.